Clinical Trial Update: Post Marketing Observational Study of Reformulated BeneFIX

View source ↗

Summary

Post-marketing observational study of reformulated BeneFIX (recombinant coagulation factor IX) for Hemophilia B has completed and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BeneFIX (recombinant coagulation factor IX concentrate)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia B | Status: COMPLETED | Results posted: 2014-09-17